GlaxoSmithKline (GSK) is taking a $400 million charge due to an investigation into drugs it manufactures that were allegedly being promoted for off-label use. One of the drugs, Wellbutrin SR, an antidepressant, was being promoted to treat bipolar disorders, which is not FDA approved. The Colorado U.S. Attorny will continue to investigate this drug, as well as nine of GSK’s best selling drug’s sales practices between 1997 and 2004.